Analysts Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Target Price at $12.20

As of March 29, 2025, Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has received a consensus recommendation of "Moderate Buy" from five investment firms monitoring the company, according to a report from Marketbeat. Among these analysts, two have suggested holding the stock, while three others have recommended buying it. The average target price set by these analysts for the next 12 months stands at $12.20.

Recent analyses by various brokerages have led to differing ratings on Inovio Pharmaceuticals. StockNews.com downgraded their rating of the company to "sell" in a report published on March 21st. Meanwhile, Royal Bank of Canada lowered its price target for Inovio, reducing it from $6.00 to $5.00, while maintaining a "sector perform" rating on March 19th. HC Wainwright also reiterated a "neutral" stance on the stock, setting a price target of $3.00 on the same date. Conversely, JMP Securities maintained a more optimistic view, reaffirming a "market outperform" rating with a price target of $18.00 in a note published on January 10th.

Stock Overview of Inovio Pharmaceuticals

On Wednesday, shares of Inovio Pharmaceuticals opened at $1.73. The company boasts a market capitalization of approximately $45.15 million, with a price-to-earnings ratio of -0.43 and a beta of 0.92. Over the past year, the stock has seen a low of $1.68 and a high of $14.75. The 50-day moving average is currently at $2.03, while the 200-day moving average is at $3.55.

Inovio Pharmaceuticals last released its quarterly earnings on March 18th, where the biopharmaceutical company reported an earnings per share (EPS) of ($0.69), surpassing analysts' expectations of ($0.87) by $0.18. The company generated $0.12 million in revenue for the quarter, exceeding the expected revenue of $0.03 million. Analysts forecast an average EPS of -4.23 for Inovio Pharmaceuticals in the current fiscal year.

Institutional Investor Activity

There have been several recent changes in the holdings of institutional investors and hedge funds regarding Inovio Pharmaceuticals. Geode Capital Management LLC increased its stake in the company by 6.7% during the third quarter, owning 621,631 shares valued at $3,594,000 after purchasing an additional 38,833 shares. Barclays PLC significantly increased its holdings by 282.6%, currently owning 34,003 shares worth $197,000 after acquiring 25,116 additional shares. FMR LLC grew its position by 370.1%, now holding 27,261 shares valued at $158,000 after buying 21,462 shares. State Street Corp also raised its stake by 11.7%, bringing its total shares to 490,662, worth approximately $2,836,000, after acquiring an additional 51,414 shares. Lastly, Green Alpha Advisors LLC increased its holdings by 103.2%, now owning 65,446 shares valued at $120,000 after purchasing 33,232 shares. Overall, institutional investors control about 26.79% of Inovio's stock.

Company Overview of Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. is a biotechnology firm engaged in the development and commercialization of DNA-based medicines to prevent and treat diseases linked to human papillomavirus (HPV), cancer, and infectious diseases. The company utilizes a unique DNA medicines platform that includes carefully designed SynCon technology which optimizes the DNA sequence targeting specific antigens, along with CELLECTRA smart device technology which facilitates the delivery of DNA plasmids.

Analysts, Pharmaceuticals, Stock